GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Baudax Bio Inc (OTCPK:BXRXQ) » Definitions » Short-Term Capital Lease Obligation

Baudax Bio (Baudax Bio) Short-Term Capital Lease Obligation : $0.34 Mil (As of Sep. 2023)


View and export this data going back to 2019. Start your Free Trial

What is Baudax Bio Short-Term Capital Lease Obligation?

Baudax Bio's Short-Term Capital Lease Obligation for the quarter that ended in Sep. 2023 was $0.34 Mil.

Baudax Bio's quarterly Short-Term Capital Lease Obligation increased from Mar. 2023 ($0.00 Mil) to Jun. 2023 ($0.61 Mil) but then declined from Jun. 2023 ($0.61 Mil) to Sep. 2023 ($0.34 Mil).


Baudax Bio Short-Term Capital Lease Obligation Historical Data

The historical data trend for Baudax Bio's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Baudax Bio Short-Term Capital Lease Obligation Chart

Baudax Bio Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Short-Term Capital Lease Obligation
Get a 7-Day Free Trial - 0.32 - - -

Baudax Bio Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
Short-Term Capital Lease Obligation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - 0.61 0.34

Baudax Bio Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.


Baudax Bio Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Baudax Bio's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.


Baudax Bio (Baudax Bio) Business Description

Industry
Traded in Other Exchanges
N/A
Address
490 Lapp Road, Malvern, PA, USA, 19355
Baudax Bio Inc is a Pharmaceutical company. The company develops and commercialize products for hospital and related acute care settings. Its products are in pipeline which includes two novel neuromuscular blocking agents, or NMBAs.
Executives
Natalie Mcandrew officer: Interim CFO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Yong Chan Kim director C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Winston J Churchill director C/O SCP PARTNERS, SUITE 300, 1200 LIBERTY RIDGE DRIVE, WAYNE PA 19087
William Ashton director C/O HARRISON CONSULTING GROUP, PO BOX 283, NEWTOWN SQUARE PA 19073
Andrew T Drechsler director 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807
Arnold M Baskies director 1235 SEQUOIA ROAD, CHERRY HILL NJ 08003
Wayne Weisman director 490 LAPP ROAD, MALVERN PA 19355
Jillian Dilmore officer: Corporate Controller/Secretary, other: PFO and PAO C/O BAUDAX BIO, INC., 490 LAPP ROAD, MALVERN PA 19355
Geraldine Henwood director, officer: President and CEO 88 SIDNEY ST, CAMBRIDGE MA 02139
Richard S Casten officer: Chief Financial Officer 490 LAPP ROAD, MALVERN PA 19355
Alfred Altomari director C/O AGILE THERAPEUTICS, INC., 101 POOR FARM ROAD, PRINCETON NJ 08540
Ryan David Lake director, officer: Chief Financial Officer KENSEY NASH CORPORATION, 735 PENNSYLVANIA DRIVE, EXTON PA 19341
Recro Pharma, Inc. 10 percent owner 1 E. UWCHLAN AVE, SUITE 112, EXTON PA 19341

Baudax Bio (Baudax Bio) Headlines

From GuruFocus

Q1 2021 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Q2 2020 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Acquires TeraImmune, Inc.

By Marketwired 06-30-2023

Baudax Bio Announces Corporate Update

By Marketwired 10-18-2023

Baudax Bio Inc Annual Shareholders Meeting Transcript

By GuruFocus Research 02-13-2024

Q1 2022 Baudax Bio Inc Earnings Call Transcript

By GuruFocus Research 02-13-2024

Baudax Bio Announces Date of Reconvened Annual Meeting

By sperokesalga sperokesalga 06-06-2023